Advancing Hereditary Cancer Testing

Myriad myRisk® report enhanced with riskScore® result

MYRIAD myRisk® Hereditary Cancer | riskScore® BREAST CANCER

myriad® WHEN DECISIONS MATTER

When a negative Hereditary Cancer Test leaves you with uncertainty

PATIENT CASE

Patient information
Age: 37 year-old female
Cancer: unaffected by breast cancer

Cancer family history
Concerning cancer family history

Hereditary cancer panel genetic result
Negative

CLINICAL UNCERTAINTY



Myriad myRisk® enhanced with riskScore® result is more comprehensive

35 genes + Personal & family history + riskScore® BREAST CANCER

myRisk® Hereditary Cancer Panel

Clinical and Cancer History Analysis

Clinically Validated Precision Medicine Tool

riskScore® predicts a woman's risk of developing breast cancer using clinical risk factors and genetic markers

REPORT EXAMPLE

Myriad myRisk® Hereditary Cancer Test

myRisk Genetic Result

MYRIAD myRisk® Hereditary Cancer — Powered by myVision®

RECEIVING HEALTHCARE PROVIDER	SPECIMEN	PATIENT
Physician Name, MD Myriad Healthcare Partners 320 Wakara Way Salt Lake City, UT 84108	Specimen Type: **Buccal** Draw Date: **Aug 15, 2017** Accession Date: **Aug 30, 2017** Report Date: **Sept 4, 2017**	Name: **Case Study 3** Date of Birth: **Feb 25, 1980** Patient ID: **0000** Gender: **Female** Accession #: **00000000-000** Requisition #: **000000**

ORDERING PHYSICIAN: **Physician Name, MD**

MYRISK GENETIC RESULT: NEGATIVE
No clinically significant mutation identified.

BREAST CANCER RISKSCORE™: REMAINING LIFETIME RISK 33.7%
This level of risk is at or above 20% threshold for consideration of modified medical managament. See riskScore® Interpretation Section for more information.

CLINICAL HISTORY ANALYSIS: NO MODIFIED MEDICAL MANAGEMENT GUIDELINES WERE IDENTIFIED BASED ON THE INFORMATION PROVIDED.
Other clinical factors may influence individualized management. This analysis may be incomplete if details about cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous.

MYRISK GENETIC RESULT: NEGATIVE
No clinically significant mutation identified.

BREAST CANCER RISKSCORE™: REMAINING LIFETIME RISK 33.7%
This level of risk is at or above 20% threshold for consideration of modified medical managament. See riskScore® Interpretation Section for more information.

CLINICAL HISTORY ANALYSIS: NO MODIFIED MEDICAL MANAGEMENT GUIDELINES WERE IDENTIFIED BASED ON THE INFORMATION PROVIDED.
Other clinical factors may influence individualized management. This analysis may be incomplete if details about cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous.

riskScore® provides a personalized 5-year and remaining lifetime cancer risk calculation

riskScore® improves the predictive value of a negative genetic test result with more precise information for cancer risk and management



riskScore® provides actionable results for women who are negative for a genetic mutation associated with a hereditary breast cancer

Uncertainty

GENETIC TEST RESULT: **NEGATIVE**

MEDICAL MANAGEMENT:

- Clinical Breast Exam and Breast Awareness

Myriad myRisk®

GENETIC TEST RESULT: **NEGATIVE**

RISKSCORE: **33.7%**

MEDICAL MANAGEMENT:

- Clinical Breast Exam and Breast Awareness
- Mammography
- MRI
- Risk Reducing Strategies

Increased confidence that genetic markers, family history and other clinical factors have been evaluated

MYRIAD myRisk® Hereditary Cancer | riskScore® BREAST CANCER

Based on research at time of product launch, riskScore® is only calculated for women of solely European ancestry1-3 under the age of 85 and without a personal history of breast cancer, LCIS, hyperplasia, atypical hyperplasia4, or a breast biopsy of unknown results. riskScore® is not calculated if a woman or a blood relative is known to carry a mutation in a breast cancer risk gene.

References:
1. Mavaddat N, et al. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015 Apr 8;107(5). PubMed. **2.** Michailidou K, et al. Largescale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013 Apr;45(4): 353-61. **3.** Michailidou K, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015 Apr;47(4):373-80. PubMed. **4.** Tyrer J, et al. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004 23:1111-30.

myriad® WHEN DECISIONS MATTER

Myriad Genetics GmbH
Leutschenbachstrasse 95
8050 Zurich
Suisse
www.myriadgenetics.eu
info@myriadgenetics.eu

Myriad Genetics España S.L.U.
Calle Caléndula 95, Miniparc II Ed.O 1ª Planta
28109 El Soto de la Moraleja - Alcobendas
España
www.myriadgenetics.es

myRISK_SCORE_BRO_06_02_20_EN_ES